Shaping the Future of Ophthalmic Drug Research and Development: Key Trends for 2030
The global ophthalmic drugs market is experiencing significant growth due to a surge in the number of individuals suffering from various eye disorders. Conditions such as glaucoma, age-related macular degeneration, dry eye syndrome, and inflammation are placing a growing burden, particularly on low and middle-income families worldwide. The International Agency for the Prevention of Blindness (IAPB) has identified age-related macular degeneration as one of the leading causes of blindness, with the number of affected patients projected to exceed 285 million by the end of 2040 on a global scale.
For More Industry Insight Read: https://www.fairfieldmarketresearch.com/report/ophthalmic-drugsmarket
According to the World Health Organization (WHO), approximately 2.2 billion individuals globally suffer from near or distance vision impairment, with around 1 billion cases going untreated but potentially preventable. This highlights the high burden of these disorders in society and the need for increased treatment options. Consequently, there is a growing demand for advanced ophthalmic drugs worldwide, driving the growth of the ophthalmic drugs market. In response to this situation, companies are forming collaborations and partnerships to meet the rising need for ophthalmic drugs. Notably, in 2022, Alcon signed an agreement to acquire Kala Pharmaceuticals Inc.'s EYSUVIS eye drops. Such developments are expected to have a positive impact on the ophthalmic drugs market. Ascending Demand for Anti-glaucoma Drugs